微信小陈
微信小章| 产品名称： | Co88BV59H21-2V67-66 |
|---|---|
| 商品货号： | TS212330 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 Cells contain Epstein-Barr Virus DNA Sequences
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Cancer |
| Applications： | This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line. Co88BV59H21-2V67-66 cells produce monoclonal antibody 88BV59 that has been shown to recognize colon tumor associated antigen (CTAA) 16.88, also referred to as CTA #1. The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538). Co88BV59H21-2 was then exposed to EBV under conditions suitable for transformation to produce Co88BV59H21-2V67-66 (TS212330). |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | diploid |
| Derivation： | This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. The patient was actively immunized with autologous tumor antigen. Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line. The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538). |
| Clinical Data： | This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. |
| Comments： | This transformed cell line was derived from B-cells of a patient undergoing surgical resection of colorectal cancer. The patient was actively immunized with autologous tumor antigen. Peripheral blood mononuclear cells (PBMNC) were transformed with Epstein-Barr virus (EBV) derived from the B95-8 marmoset cell line. Co88BV59H21-2V67-66 cells produce monoclonal antibody 88BV59 that has been shown to recognize colon tumor associated antigen (CTAA) 16.88, also referred to as CTA #1. Both the 88BV59 antibody and the 16-88 antibody recognize the same tumor associated antigen, but react with different epitopes on that antigen. The 16-88 antibody (LiCO 16-88) is available as ATCC HB-8495. The CO 88BV59 cell line was fused with a human-mouse heteromyeloma to produce a cell line designated Co88BV59H21-2 (ATCC CRL-11538). Co88BV59H21-2 was then exposed to EBV under conditions suitable for transformation to produce Co88BV59H21-2V67-66 (TS212330). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 8 x 105 viable cells/mL.
Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG3; kappa light chain |
| Name of Depositor： | Organon Teknika Biotech Research Institute |
| Deposited As： | human |
| U.S. Patent Number： | |
| References： | Hanna M Jr., et al. Tumor associated monocoloal antibodies derived from human B-cell line. US Patent 4,997,762 dated Mar 5 1991 Hanna MG Jr., et al. Tumor associated monoclonal antibodies. US Patent 5,474,755 dated Dec 12 1995 Butler SM, et al. Tumor associated epitope. US Patent 5,951,985 dated Sep 14 1999 De Jager R, et al. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin. Nucl. Med. 23: 165-179, 1993. PubMed: 8511602 Moffat FL Jr., et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J. Nucl. Med. 36: 738-745, 1995. PubMed: 7738642 Serafini AN, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J. Clin. Oncol. 16: 1777-1787, 1998. PubMed: 9586891 Wolff BG, et al. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study. Dis. Colon Rectum 41: 953-962, 1998. PubMed: 9715149 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |